Last reviewed · How we verify
IgPro10
IgPro10, marketed by CSL Behring, is an immunoglobulin product with a well-established presence in the market. The key composition patent for IgPro10 is set to expire in 2028, providing a significant period of exclusivity and competitive advantage. The primary risk to IgPro10 is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | IgPro10 |
|---|---|
| Also known as | Human normal immunoglobulin, Privigen |
| Sponsor | CSL Behring |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Two Dose Levels of Privigen in Pediatric CIDP (PHASE4)
- Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (PHASE3)
- Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc) (PHASE2)
- Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc) (PHASE2)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) (PHASE3)
- A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP) (PHASE4)
- Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) (PHASE3)
- Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |